The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of a phase I study of bendamustine in combination with ofatumumab, carboplatin, and etoposide (BOCE) for refractory or relapsed aggressive B-cell non-Hodgkin lymphomas (NHL).
Sameh Gaballa
No relevant relationships to disclose
Neil David Palmisiano
No relevant relationships to disclose
Aakanksha Asija
No relevant relationships to disclose
Andrew E. Chapman
No relevant relationships to disclose
Jennifer K. Cloud
No relevant relationships to disclose
Joanne E. Filicko-O'Hara
No relevant relationships to disclose
Lewis J. Rose
No relevant relationships to disclose
Michael J. Ramirez
No relevant relationships to disclose
Onder Alpdogan
No relevant relationships to disclose
Neal Flomenberg
No relevant relationships to disclose
Barbara Pro
Research Funding - GlaxoSmithKline
Elena Gitelson
No relevant relationships to disclose
Mark Adam Weiss
Research Funding - GlaxoSmithKline